Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light in the treatment of facial cutaneous squamous cell carcinoma in situ
Journal of Cosmetic Dermatology · 2023
DOI: 10.1111/jocd.15886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2023. Verfasst von Mark S Nestor und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical and Cosmetic Research, Aventura, Florida, USA. Hauptthemen laut MEDLINE: Photochemotherapy, Carcinoma, Squamous Cell, Lasers, Dye, Skin Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sun Pharma.
Abstract (Originalsprache)
Background
Squamous cell carcinoma (SCC) is the second most common cutaneous malignancy, after basal cell carcinoma (BCC). Photodynamic therapy (PDT) involves converting a photosensitizer to reactive oxygen intermediates, which preferentially bind to hyperproliferative tissue. The most commonly used photosensitizers are methyl aminolevulinate and aminolevulinic acid (ALA). Presently, ALA‐PDT is approved in the US and Canada for the treatment of actinic keratoses on the face, scalp, and upper extremities.
Aims
This cohort study evaluated the safety, tolerability, and efficacy of aminolevulinic acid, pulsed dye laser, and photodynamic therapy (ALA‐PDL‐PDT) for treatment of facial cutaneous squamous cell carcinoma in situ (isSCC).
Methods
Twenty adult patients with biopsy‐confirmed isSCC on the face were recruited. Only lesions 0.4–1.3 cm in diameter were included. Patients underwent two treatments with ALA‐PDL‐PDT spaced 30 days apart. The isSCC lesion was then excised 4–6 weeks following the second treatment for histopathological assessment.
Results
No residual isSCC was detected in 17/20 (85%) patients. Two of the patients with residual isSCC had skip lesions present that explained the treatment failure. Excluding the patients with skip lesions, the posttreatment histological clearance rate was 17/18 (94%). Minimal side effects were reported.
Limitations
Our study was limited by small sample size and lack of long‐term recurrence data.
Conclusions
The ALA‐PDL‐PDT protocol is a safe and well‐tolerated treatment option for isSCC on the face, providing excellent cosmetic and functional results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical and Cosmetic Research, Aventura, Florida, USA.
- Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Department of Surgery, Division of Plastic Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
ORCID-Profile: Mark S Nestor
Förderung
- Sun Pharma
Zitieren
APA
Nestor, M. S., Han, H., Ceci, F. M., Lawson, A., & Gade, A. (2023). Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light in the treatment of facial cutaneous squamous cell carcinoma in situ. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.15886
Vancouver
Nestor MS, Han H, Ceci FM, Lawson A, Gade A. Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light in the treatment of facial cutaneous squamous cell carcinoma in situ. Journal of Cosmetic Dermatology. 2023. doi:10.1111/jocd.15886
BibTeX
@article{Nestor2023,
author = {Nestor, Mark S and Han, Haowei and Ceci, Francesca M and Lawson, Alec and Gade, Anita},
title = {Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light in the treatment of facial cutaneous squamous cell carcinoma in situ},
journal = {Journal of Cosmetic Dermatology},
year = {2023},
doi = {10.1111/jocd.15886}
}
EUVIMED